AUTLAutolus Therapeutics plc

Nasdaq autolus.com


$ 4.16 $ 0.05 (1.22 %)    

Thursday, 09-May-2024 15:59:55 EDT
QQQ $ 441.33 $ 0.87 (0.2 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 3.37 (0.65 %)
TLT $ 90.69 $ 0.50 (0.55 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 4.17
$ 4.11
$ 0.00 x 0
$ 0.00 x 0
$ 4.09 - $ 4.27
$ 1.79 - $ 7.45
1,679,145
na
1.09B
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 autolus-therapeutics-announces-abstract-for-longer-term-follow-up-and-additional-data-analysis-of-pivotal-phase-2-felix-study-of-obe-cel-for-adult-rr-b-all-selected-for-an-oral-presentation-at-asco

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...

 needham-reiterates-buy-on-autolus-therapeutics-maintains-9-price-target

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

 truist-securities-maintains-buy-on-autolus-therapeutics-raises-price-target-to-11

Truist Securities analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from ...

 needham-maintains-buy-on-autolus-therapeutics-maintains-9-price-target

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 needham-maintains-buy-on-autolus-therapeutics-raises-price-target-to-9

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $8 to $9.

Core News & Articles

BioNTech SE (NASDAQ:BNTX, ", BioNTech", )))), a next-generation immunotherapy company pioneering novel therapies for ca...

 needham-maintains-buy-on-autolus-therapeutics-raises-price-target-to-8

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $7 to $8.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION